Literature DB >> 16146920

The cross-species A3 adenosine-receptor antagonist MRS 1292 inhibits adenosine-triggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure.

Hui Yang1, Marcel Y Avila, Kim Peterson-Yantorno, Miguel Coca-Prados, Richard A Stone, Kenneth A Jacobson, Mortimer M Civan.   

Abstract

PURPOSE: Antagonists to A3 adenosine receptors (ARs) lower mouse intraocular pressure (IOP), but extension to humans is limited by species variability. We tested whether the specific A3AR antagonist MRS 1292, designed to cross species, mimicks the effects of other A3AR antagonists on cultured human nonpigmented ciliary epithelial (NPE) cells and mouse IOP.
METHODS: NPE cell volume was monitored by electronic cell sorting. Mouse IOP was measured with the Servo-Null Micropipette System.
RESULTS: Adenosine triggered A3AR-mediated shrinkage of human NPE cells. Shrinkage was blocked by MRS 1292 (IC50 = 42 +/- 11 nM, p < 0.01) and by another A3AR antagonist effective in this system, MRS 1191. Topical application of the A3AR agonist IB-MECA increased mouse IOP. MRS 1292 reduced IOP by 4.0 +/- 0.8 mmHg at 25-microM droplet concentration (n = 10, p < 0.005).
CONCLUSIONS: MRS 1292 inhibits A3AR-mediated shrinkage of human NPE cells and reduces mouse IOP, consistent with its putative action as a cross-species A3 antagonist.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16146920      PMCID: PMC3471215          DOI: 10.1080/02713680590953147

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  42 in total

Review 1.  A(3) adenosine receptor ligands: history and perspectives.

Authors:  P G Baraldi; B Cacciari; R Romagnoli; S Merighi; K Varani; P A Borea; G Spalluto
Journal:  Med Res Rev       Date:  2000-03       Impact factor: 12.944

2.  Structure-activity relationships of adenosine A3 receptor ligands: new potential therapy for the treatment of glaucoma.

Authors:  Takashi Okamura; Yasuhisa Kurogi; Kinji Hashimoto; Seiji Sato; Hiroshi Nishikawa; Kimio Kiryu; Yoshimitsu Nagao
Journal:  Bioorg Med Chem Lett       Date:  2004-07-16       Impact factor: 2.823

Review 3.  The ins and outs of aqueous humour secretion.

Authors:  Mortimer M Civan; Anthony D C Macknight
Journal:  Exp Eye Res       Date:  2004-03       Impact factor: 3.467

4.  Reliable measurement of mouse intraocular pressure by a servo-null micropipette system.

Authors:  M Y Avila; D A Carré; R A Stone; M M Civan
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-07       Impact factor: 4.799

5.  Expression of Na,K-ATPase alpha subunit isoforms in the human ciliary body and cultured ciliary epithelial cells.

Authors:  P Martin-Vasallo; S Ghosh; M Coca-Prados
Journal:  J Cell Physiol       Date:  1989-11       Impact factor: 6.384

6.  Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group.

Authors: 
Journal:  Am J Ophthalmol       Date:  1998-10       Impact factor: 5.258

7.  The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group.

Authors: 
Journal:  Am J Ophthalmol       Date:  1998-10       Impact factor: 5.258

Review 8.  A(3) adenosine receptor antagonists.

Authors:  C E Müller
Journal:  Mini Rev Med Chem       Date:  2001-11       Impact factor: 3.862

9.  Intraocular adenosine levels in normal and ocular-hypertensive patients.

Authors:  Bradley S Daines; Alexander R Kent; Melissa S McAleer; Craig E Crosson
Journal:  J Ocul Pharmacol Ther       Date:  2003-04       Impact factor: 2.671

10.  N6-Substituted adenosine derivatives: selectivity, efficacy, and species differences at A3 adenosine receptors.

Authors:  Zhan-Guo Gao; Joshua B Blaustein; Ariel S Gross; Neli Melman; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2003-05-15       Impact factor: 5.858

View more
  30 in total

Review 1.  Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.

Authors:  Rebecca K Donegan; Raquel L Lieberman
Journal:  J Med Chem       Date:  2015-09-25       Impact factor: 7.446

Review 2.  Recent developments in adenosine receptor ligands and their potential as novel drugs.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Biochim Biophys Acta       Date:  2010-12-23

3.  Purine receptors: GPCR structure and agonist design.

Authors:  Kenneth A Jacobson; Soo-Kyung Kim; Stefano Costanzi; Zhan-Guo Gao
Journal:  Mol Interv       Date:  2004-12

4.  Conversion of A3 adenosine receptor agonists into selective antagonists by modification of the 5'-ribofuran-uronamide moiety.

Authors:  Zhan-Guo Gao; Bhalchandra V Joshi; Athena M Klutz; Soo-Kyung Kim; Hyuk Woo Lee; Hea Ok Kim; Lak Shin Jeong; Kenneth A Jacobson
Journal:  Bioorg Med Chem Lett       Date:  2005-11-10       Impact factor: 2.823

Review 5.  Adenosine receptors as therapeutic targets.

Authors:  Kenneth A Jacobson; Zhan-Guo Gao
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

6.  Functionalized congeners of A3 adenosine receptor-selective nucleosides containing a bicyclo[3.1.0]hexane ring system.

Authors:  Dilip K Tosh; Moshe Chinn; Andrei A Ivanov; Athena M Klutz; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

7.  Structure-activity relationships of truncated adenosine derivatives as highly potent and selective human A3 adenosine receptor antagonists.

Authors:  Shantanu Pal; Won Jun Choi; Seung Ah Choe; Cara L Heller; Zhan-Guo Gao; Moshe Chinn; Kenneth A Jacobson; Xiyan Hou; Sang Kook Lee; Hea Ok Kim; Lak Shin Jeong
Journal:  Bioorg Med Chem       Date:  2009-03-25       Impact factor: 3.641

8.  Invited Lectures : Overviews Purinergic signalling: past, present and future.

Authors: 
Journal:  Purinergic Signal       Date:  2006-05-15       Impact factor: 3.765

Review 9.  Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering.

Authors:  Kenneth A Jacobson; Athena M Klutz; Dilip K Tosh; Andrei A Ivanov; Delia Preti; Pier Giovanni Baraldi
Journal:  Handb Exp Pharmacol       Date:  2009

Review 10.  Introduction to adenosine receptors as therapeutic targets.

Authors:  Kenneth A Jacobson
Journal:  Handb Exp Pharmacol       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.